Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 16901
Country/Region: Ethiopia
Year: 2016
Main Partner: Southern Nations, Nationalities, and Peoples' Region - Ethiopia
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: HHS/CDC
Total Funding: $4,862,338 Additional Pipeline Funding: $110,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $578,607
Care: TB/HIV (HVTB) $191,812
Care: Pediatric Care and Support (PDCS) $90,011
Laboratory Infrastructure (HLAB) $152,426
Strategic Information (HVSI) $200,099
Health Systems Strengthening (OHSS) $61,872
Biomedical Prevention: Blood Safety (HMBL) $27,963
Testing: HIV Testing and Counseling (HVCT) $95,087
Sexual Prevention: Other Sexual Prevention (HVOP) $30,366
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $391,624
Treatment: Adult Treatment (HTXS) $2,819,691
Treatment: Pediatric Treatment (PDTX) $222,780
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 172
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 146
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 198
GEND_GBV Number of people receiving post-GBV care 2017 344
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 70,954
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 73,856
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 386,929
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 209,400
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 741,139
HTS_TST Service Delivery Point (Facility): Inpatient 2017 65,646
HTS_TST Service Delivery Point (Facility): Other PITC 2017 43,733
HTS_TST Service Delivery Point (Facility): Outpatient 2017 251,586
HTS_TST Service Delivery Point (Facility): PMTCT 2017 192,763
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 49,222
HTS_TST Service Delivery Point (Facility): VCT 2017 136,742
HTS_TST Sum of Aggregated Age/Sex <15 2017 144,810
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 596,329
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 741,139
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 239
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 249
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,444
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,182
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 600
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 600
KP_PREV Total estimated number of key population in the catchment area 2017 6,991
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 6,991
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 24
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 24
LAB_PT CD4: Number of laboratories that perform this testing 2017 32
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 85
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 85
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 85
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 22
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 22
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 85
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program 2017 1
LAB_PT TB diagnostics (Culture/DST): Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 3
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 18
PMTCT_ART Already on ART at beginning of current pregnancy 2017 2
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,163
PMTCT_ART New on ART 2017 2
PMTCT_ART New on ART 2017 379
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 172,192
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 549
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,121
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 284
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 12
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 18
PMTCT_EID Sum of Infant Age disaggregates 2017 1,405
PMTCT_STAT By: Known positives at entry 2017 2
PMTCT_STAT By: Known positives at entry 2017 1,236
PMTCT_STAT By: Number of new positives identified 2017 2
PMTCT_STAT By: Number of new positives identified 2017 366
PMTCT_STAT Number of new ANC and L&D clients 2017 557
PMTCT_STAT Number of new ANC and L&D clients 2017 182,153
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 549
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 172,192
PMTCT_STAT Sum of Positives Status disaggregates 2017 4
PMTCT_STAT Sum of Positives Status disaggregates 2017 1,602
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 1,609
PP_PREV Total number of people in the target population 2017 1,925
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 83
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 9
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 129
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 226
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 226
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,121
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 637
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 639
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 844
TB_SCREENDX Screen Result: Screened Positive for TB 2017 3,051
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 16,769
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 10,689
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 1,306
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 1,468
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 30,232
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 211
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,325
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 284
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,678
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 3,498
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 3,614
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,746
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,911
TX_CURR Aggregated Age/Sex: 15+ Female 2017 21,310
TX_CURR Aggregated Age/Sex: 15+ Male 2017 13,747
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 38,716
TX_CURR Sum of Aggregated Age/Sex <15 2017 3,657
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 35,057
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 38,714
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 352
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 391
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 2,760
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,671
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 5,176
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 5,174
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 24,869
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 19,911
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 909
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 993
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 10,946
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 7,063
TX_PVLS Numerator: Indication: Routine 2017 15,926
TX_PVLS Numerator: Indication: Targeted 2017 3,985
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,135
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,239
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 13,681
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 8,832
TX_PVLS_den Denominator: Indication: Routine 2017 19,908
TX_PVLS_den Denominator: Indication: Targeted 2017 4,979
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 179
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 207
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,025
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,099
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 3,394
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 3,910
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 195
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 234
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,250
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,231
Cross Cutting Budget Categories and Known Amounts Total: $632,516
Food and Nutrition: Policy, Tools, and Service Delivery $75,219
Renovation $360,000
Motor Vehicles: Purchased $160,000
Key Populations: Sex Workers $16,146
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $21,151
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation